NEKTAR THERAPEUTICS 4

President & CEO Robin Howard W sold 418 shares of Nektar Therapeutics common stock on 2026-08-18 to cover tax withholding from RSU vesting.

On August 18, 2026, President & CEO Robin Howard W of Nektar Therapeutics reported the sale of 418 shares of common stock at a weighted average price of approximately $71.98 per share, for proceeds of about $30,100, in a transaction explicitly disclosed as solely to cover required tax withholding obligations arising from RSU vesting and not as a discretionary sale; following this sale, the reporting person held 54,627 shares directly, and an additional 28 shares were reported as held indirectly by the spouse.

Filing Facts

CIK

906709

Ticker

NKTR

Form

4

Source Type

fda

Accession

0001193125-26-359586

Alert Tier

5